Oxycodone controlled-release - Intellipharmaceutics

Drug Profile

Oxycodone controlled-release - Intellipharmaceutics

Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Oxycodone CR - Intellipharmaceutics; Oxycodone ER - Intellipharmaceutics; Oxycodone hydrochloride extended-release tablets - Intellipharmaceutics; Rexista oxycodone

Latest Information Update: 27 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intellipharmaceutics International
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 08 May 2018 Intellipharmaceutics plans human abuse liability trial for oral route in 2018
  • 08 May 2018 Phase I development is ongoing in Canada (PO)
  • 08 May 2018 Intellipharmaceutics announces intention to re-submit NDA to US FDA for Pain later in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top